Germany imported 50,539 kg of cannabis flower for medical and medical-scientific use in the first quarter of 2026, and Canadian producers supplied 53% of that volume, according to figures published by BfArM. Trade at that scale moves on documentation, not on relationships.
Cannabis import requirements are the conditions a destination country sets before a shipment may cross its border. There are four of them: an import authorisation held by your buyer, proof that your site meets a quality standard that country accepts, batch data that satisfies its test panel, and a matching export permit issued to you by Health Canada under the Cannabis Act.
Germany, Australia and Israel take most of the medical volume Canadian licence holders quote on. The four requirement families are identical in all three markets. The evidence each regulator will accept is not, and in every one of them an acceptance rule or a trade rule moved during 2026.
What cannabis import requirements have in common
Local vocabulary differs, but every regulated medical market gates the same four things:
- An import licence or permit held by the receiving company, usually issued per consignment
- Evidence that your production site meets a quality standard the destination recognises
- Batch release data from an accredited laboratory, matched to the destination test panel
- A Canadian export permit naming the shipment, the buyer and the foreign authorisation
Sequence matters more than the list. Health Canada issues an export permit against the destination country's import authorisation, so your buyer's paperwork sets the schedule rather than yours. Our walkthrough of the Health Canada export permit process covers the Canadian half of that sequence step by step, and the two-permit chain explains how the foreign and Canadian permits interlock.
Everything past that point is local. Germany reads your quality evidence through European pharmaceutical law, Australia reads it through a therapeutic goods standard, and Israel reads it through its own IMC standards. One question, three different acceptable answers.
Germany, Australia and Israel compared
These are the points that decide whether a consignment ships or sits.
| Market | Buyer-side authorisation | Quality evidence accepted | What moved in 2026 |
|---|---|---|---|
| Germany | BfArM import licence plus a permit per consignment | EU-GMP at manufacturing, GACP at cultivation, pharmacopoeia testing | Cultivar approval clarified, prescribing rules under amendment |
| Australia | ODC import licence up to 12 months plus a permit per consignment | TGO 93 conformity, accepted GMP standard for overseas manufacture | TGA review of the unapproved access framework |
| Israel | Ministry of Health import licence through the cannabis agency | IMC-GAP at cultivation, IMC-GMP after harvest | Anti-dumping investigation into Canadian cannabis reopened |
Germany sets the highest manufacturing bar. EU-GMP certification is required at the manufacturing step and GACP compliance at cultivation, with flower tested against the German Pharmacopoeia monograph before it reaches pharmacy distribution. BfArM also clarified its cultivar approval process in late 2025 under heightened EU-GMP scrutiny, which matters whenever you introduce new genetics into an existing supply agreement. Our guide to German export requirements works through the document set.
Australia gates on the product standard instead of the country of origin. TGO 93 sets the minimum quality requirements for medicinal cannabis imported into or supplied in Australia and places no restriction on where the product was grown. It does require that overseas manufacturing steps meet one of the GMP standards named in the order, with the Australian sponsor holding that evidence. Import runs through the Office of Drug Control: a licence valid for up to 12 months, plus a permit for each consignment under the Customs (Prohibited Imports) Regulations 1956. Only delta-9-tetrahydrocannabinol may be imported. The TGA also runs random and targeted TGO 93 audits on product already in market, so conformity is not a one-time gate. See our Australian export guide for the permit workflow.
Israel accepts a wider band of evidence. The Israel Medical Cannabis Agency licenses import through the Ministry of Health and works to IMC-GAP at cultivation and IMC-GMP after harvest. That combination has historically made Israel an easier first market than Germany for producers without EU-GMP. Canada supplies the clear majority of Israeli cannabis imports, and that position is now a trade question rather than a regulatory one. Background sits in our IMCA import permit guide.
The four-gate import readiness test
Before quoting a new market, run the file through four gates in the order a regulator will check them. Failing any one of them stops the shipment.
Gate 1: the buyer's authorisation
Confirm the receiving company holds a current import licence and, where the market requires one, a permit covering your specific consignment. Ask for the permit number and its expiry date rather than a verbal assurance. In Germany and Australia the permit is shipment-level, so a buyer with a valid annual licence still cannot lawfully receive goods without it.
Gate 2: quality evidence in the accepted form
Check which certificate the destination recognises and which body issued it. EU-GMP certificates for manufacturers outside the EU come from national competent authorities such as the German inspectorate system, Portugal's INFARMED or the Danish Medicines Agency, not from the European Medicines Agency. Australia asks the sponsor to hold GMP evidence for every overseas manufacturing step. Israel works to its own IMC certifications. If you hold one standard and need another, our explainer on EU QP batch release covers what happens to your certificate once product lands.
Gate 3: batch data that matches the local panel
Your certificate of analysis has to answer the destination's questions, not Canada's. Cannabinoid content, microbial limits, heavy metals, pesticides and mycotoxins including ochratoxin A all sit inside TGO 93, and German pharmacopoeia testing carries its own expectations. Release testing through an ISO/IEC 17025 accredited laboratory is the baseline every buyer starts from. Our guide on testing requirements across four export markets sets out the panels side by side.
Gate 4: the Canadian export permit
Apply once the destination authorisation exists. The Canadian permit is shipment-specific, references the foreign import permit, and covers cannabis destined for medical or scientific purposes only. Build its lead time into the contract rather than into the shipping window.
Where Canadian shipments stall in 2026
Most stalled consignments fail on a detail that was visible weeks earlier. Four patterns recur.
Entity mismatch is the simplest. The company named on the foreign import permit has to match the company named on the Canadian export permit and on the commercial invoice. Any variation in legal name, address or licence number invites a query at the border.
Certification scope is the second. BfArM has held since 2025 that a valid GMP certificate must cover the drying step, which means GACP-only certification upstream is not sufficient for flower entering GMP-certified processing. Producers sourcing biomass across several cultivation sites carry that exposure into every shipment.
Test panel gaps are third. A batch that clears Canadian release testing can still miss a destination limit, and the fix is a retest at your cost with the shipping window already spent.
Policy movement is fourth, and 2026 has been busy. Germany's federal cabinet approved a draft amendment in October 2025 that would require in-person doctor contact for flower prescriptions, which affects demand rather than admissibility. In February 2026 the TGA described Australia's unapproved-access framework as no longer fit for purpose, and the Office of Drug Control has consulted on revised supply pathways. On 5 August 2026 Israel's Trade Remedies Commissioner opened a fresh anti-dumping investigation into Canadian medical cannabis, with a foreign exporter questionnaire due by 7 September 2026. None of this changes the four gates. All of it changes the commercial case for a given market, so review supply agreements country by country rather than as a block.
AlphaLeaf is a Health Canada Licensed Producer in Montreal growing indoor, hand-trimmed flower from refined genetics. We hold export authorisation under the Cannabis Act and maintain the ISO-certified batch testing and full traceability records that German, Australian and Israeli import partners expect to review before a first consignment moves.
If you are evaluating a Canadian supply partner for one of these markets, our international supply page sets out the documentation that travels with every batch. You can start a conversation through our contact page.
Frequently Asked Questions
What documents does a Canadian LP need to export cannabis to Germany?
Four: an import licence and consignment permit held by the German importer and issued by BfArM, an EU-GMP certificate covering your manufacturing steps, GACP evidence for cultivation, and a shipment-specific export permit from Health Canada. Batch testing to German Pharmacopoeia expectations sits behind all four.
Does Australia accept Canadian GMP certification for medicinal cannabis?
Australia requires overseas manufacturing steps to meet one of the GMP standards named in TGO 93, and the Australian sponsor must hold evidence of that compliance. TGO 93 places no restriction on country of origin, so Canadian product is admissible once the GMP evidence and the ODC import licence and consignment permit are in place.
What quality standard does Israel require for imported cannabis?
Israel applies its own IMC standards, with IMC-GAP at cultivation and IMC-GMP after harvest, administered by the Israel Medical Cannabis Agency under the Ministry of Health. That acceptance band has historically been wider than Germany's EU-GMP requirement, which is why many Canadian producers ship to Israel before Europe.
Can Health Canada issue an export permit before the buyer holds an import permit?
No. A Canadian export permit is issued against the destination country's import authorisation, so the buyer's permit sets the schedule. Apply on the Canadian side once the importer confirms its permit number and validity dates.
Who issues EU-GMP certificates to cannabis producers outside the EU?
National competent authorities issue them, not the European Medicines Agency. Authorities with documented cannabis inspection experience include the German inspectorate system, Portugal's INFARMED, the Danish Medicines Agency and Malta's Medicines Authority. The EMA coordinates GMP policy and maintains the EudraGMDP database.
